Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 32, showing 5 Applications out of 157 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s)

1.

ECCT/23/03/05   SKY-06
    A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS   PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER   
Principal Investigator(s)
1. Dr Primus Ochieng
Site(s) in Kenya
1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

2.

ECCT/22/05/02   BREATHER Plus
        A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
View

3.

ECCT/19/07/01   IMPROVE-2
      chemoprevention with monthly IPTp with dihydroartemisinin-piperaquine for malaria in HIV-infected pregnant participants on daily cotrimoxazole in Kenya and Malawi: a multi-centre placebo-controlled trial(IMPROVE-2).    
Principal Investigator(s)
1. Hellen Cherono Barsosio
2. Simon Kariuki
Site(s) in Kenya
1. Ahero Sub-County Hospital (Kisumu county)
2. Rabuor Sub-County Hospital (Kisumu county)
3. Akala Sub-County Hospital (Siaya county)
 
View

4.

ECCT/22/01/01   ASTEFANIA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

5.

21/06/16   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county)
2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county)
3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county)
4. Partners in Health Research and Development, Thika (Kiambu county)
5. KARGENO RESEARCH AND POLICY HUB (Kisumu county)
6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county)
7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county)
9. Aga Khan University Hospital (Nairobi City county)
10. KEMRI CCR-Butere County Hospital Site (Kakamega county)
 
View